Sanofi (SNY)

• Market cap: $130B
• 1 day: 1.87%
• 5 days: 6.78%
• 1 month: 6.82%
• 3 months: -3.67%
• 6 months: 1.23%
• Year to date: 7.26%
• 1 year: 1.69%
• 5 years: 2.95%
• 10 years: 10.54%

About: Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Employees: 87,994

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

56% more first-time investments, than exits

New positions opened: 92 | Existing positions closed: 59

31% more call options, than puts

Call options by funds: $125M | Put options by funds: $95.4M

30% more funds holding in top 10

Funds holding in top 10: 10 [Q2] → 13 (+3) [Q3]

24% more repeat investments, than reductions

Existing positions increased: 288 | Existing positions reduced: 232

17% more capital invested

Capital invested by funds: $14B [Q2] → $16.4B (+$2.34B) [Q3]

3% more funds holding

Funds holding: 715 [Q2] → 740 (+25) [Q3]

0.39% less ownership

Funds ownership: 22.78% [Q2] → 22.39% (-0.39%) [Q3]